EMA Archives - HealthQuill

British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a standard-of-care combination, according to the company.

GSK’s blood cancer test drug halves risk of disease progression: Data

British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a.

by HealthQuill
June 3, 2024
0 Comments

FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical trials showed “significant” improvement in overall survival rates.

Drugs Health Pharma

J&J’s metastatic bladder cancer drug gets full FDA approval

HQ Team January 21, 2024: The FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical.

by HealthQuill
January 21, 2024
0 Comments

Semaglutide based weightloss drugs tied to increased suicide risk in a new study

Drugs Health Pharma

EMA expands probe into suicidal thoughts linked to weight loss drugs

HQ Team December 2, 2023: The European Medicines Agency (EMA) is intensifying its investigation into the potential link between certain GLP-1 receptor agonist.

by HealthQuill
December 2, 2023
1 Comment

Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by the FDA.

Drugs Health Pharma

Merck gets priority review nod from USFDA for hypertension drug

HQ Team September 28, 2023: Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by.

by HealthQuill
September 28, 2023
0 Comments

The European Medicines Agency has recommended the stoppage of conditional marketing authorisation for GSK’s Blenrep (belantamab mafodotin), a medicine used to treat cancer of the bone marrow.

Drugs Health Pharma

EMA recommends stopping sale of GSK’s blood cancer drug in EU

The European Medicines Agency has recommended the stoppage of conditional marketing authorisation for GSK’s Blenrep (belantamab mafodotin), a medicine used to treat cancer of.

by HealthQuill
September 15, 2023
0 Comments

Roche’s atezolizumab drug Tecentriq, to treat cancer, was approved by Britain’s Medicines and Healthcare Products Regulatory Agency.

Drugs Health Pharma

Roche’s under-the-skin cancer injection gets Britain’s nod

HQ Team August 30, 2023: Roche’s atezolizumab drug Tecentriq, to treat cancer, was approved by Britain’s Medicines and Healthcare Products Regulatory Agency. Tecentriq.

by HealthQuill
August 30, 2023
0 Comments

British pharmaceutical firm, GSK Plc., has got marketing authorization from the European Medicines Authority for its injectable, and tablets, cabotegravir, to prevent HIV.

Drugs Health Pharma

Britain’s GSK gets EMA clearance for drug to prevent HIV

HQ Team July 24, 2023: British pharmaceutical firm, GSK Plc., has got marketing authorization from the European Medicines Authority for its injectable, and.

by HealthQuill
July 24, 2023
0 Comments

Pfizer Inc. announced that USFDA has accepted its biologics license application for treating bleeding disorders in adults through gene therapy.

Drugs Medical Pharma

FDA, EMA accept Pfizer’s BLP application for hemophilia therapy

HQ Team June 26, 2023: Pfizer Inc. announced that USFDA has accepted its biologics license application for treating bleeding disorders in adults through.